Novo Nordisk to offer Ozempic at $499 per month to cash-paying US customers - MarketScreener
MarketScreenerarrow_outwardNovo Nordisk to offer Ozempic at $499 per month to cash-paying US customers - Reuters
Reutersarrow_outwardNovo Nordisk A/S (NVO) Delivers 18% Sales Growth in H1 2025
Yahoo Financearrow_outward1 Stock Down 40% This Year to Buy and Hold
The Motley Foolarrow_outwardIt's Time To Be All-In On Novo Nordisk (NYSE:NVO)
Seeking Alphaarrow_outwardGoodRx partners with Novo Nordisk to offer Ozempic, Wegovy for $499 monthly - StreetInsider
StreetInsiderarrow_outwardNovo Nordisk to offer Ozempic for $499 per month - TradingView
TradingViewarrow_outwardGoodRx, Novo Nordisk partner to offer discounted GLP-1s at the pharmacy counter - Endpoints News
Endpoints Newsarrow_outwardNovo Nordisk's Weight-Loss Drug Wegovy Approved to Treat Liver Disease - Investopedia
Investopediaarrow_outwardNovo Wins MASH Approval for Wegovy - BioSpace
BioSpacearrow_outwardWeight-loss drug Wegovy launches in South Africa - Semafor
Semaforarrow_outwardSHAREHOLDER ALERT: Bernstein Liebhard LLP Announces A - GlobeNewswire
GlobeNewswirearrow_outwardDespite FDA ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market - Pharma Voice
Pharma Voicearrow_outwardNovo Nordisk shares jump after US approves Wegovy for liver disease - Latest news from Azerbaijan
Latest news from Azerbaijanarrow_outwardPalo Alto, Novo Nordisk and Unitedhealth rise premarket; Tesla falls - Investing.com
Investing.comarrow_outwardFDA Grants Accelerated Approval to Novo Nordisk’s Wegovy for Treating MASH - geneonline.com
Geneonline.comarrow_outwardIs Novo Nordisk's 70% Stock Plunge a Golden Opportunity for Value Investors? - AInvest
AInvestarrow_outwardNovo Nordisk Stock Is Jumping. Weight-Loss Drug Wegovy Has Something to Do With It. - Barron's
Barron'sarrow_outwardNovo Nordisk’s Wegovy approved to treat liver disease in US, 18 Aug 2025 11:39 - Shares Magazine
Shares Magazinearrow_outwardNovo Nordisk claims first GLP-1 approval in MASH - pharmaphorum
Pharmaphorumarrow_outwardNovo Nordisk shares pop 5% after Wegovy receives U.S. approval for liver disease - MSN
MSNarrow_outwardWhy Weight-Loss Drugmaker Novo Nordisk’s Stock Is Rising Premarket Today - Stocktwits
Stocktwitsarrow_outwardNovo Nordisk notes great potential for Wegovy in new US MASH market - medwatch.com
Medwatch.comarrow_outwardNovo Nordisk shares pop 5% after Wegovy receives U.S. approval for liver disease - CNBC
CNBCarrow_outwardNVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
Morningstararrow_outwardNVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
PR Newswirearrow_outwardNVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm - WV News
WV Newsarrow_outwardFDA Approves Novo Nordisk's Weight-Loss Drug Wegovy As First GLP-1 Therapy For MASH - RTTNews
RTTNewsarrow_outwardTrending tickers: Novo Nordisk, Palo Alto Networks, Walmart, Soho House and Nio - uk.finance.yahoo.com
Uk.finance.yahoo.comarrow_outwardNovo Nordisk secures FDA approval for Wegovy to treat MASH - World Pharmaceutical Frontiers
World Pharmaceutical Frontiersarrow_outwardStocks to Watch Monday: Novo Nordisk, Soho House, UnitedHealth, First Solar - The Wall Street Journal
The Wall Street Journalarrow_outwardWhy Novo Nordisk Shares Are Soaring Today - TipRanks
TipRanksarrow_outwardNovo Nordisk Secures FDA Approval Amplifying Market Prospects - StocksToTrade
StocksToTradearrow_outwardNovo Nordisk’s Wegovy Gets US Approval for Liver Disease - Bloomberg.com
Bloomberg.comarrow_outwardNovo Nordisk’s obesity drug Wegovy cleared to treat live disease MASH - statnews.com
Statnews.comarrow_outwardNovo Nordisk's Wegovy is first GLP-1 to break into MASH - FirstWord Pharma
FirstWord Pharmaarrow_outwardWeight-loss weariness and Trump threats wipe $250bn off Novo Nordisk and Eli Lilly - Financial Times
Financial Timesarrow_outwardThe world needs more than drugs to fight obesity, writes Novo Nordisk’s ex-boss - The Economist
The Economistarrow_outwardHow Ozempic’s Maker Lost Its Shine After Creating a Wonder Drug - The New York Times
The New York Timesarrow_outwardDrugmaker Novo Nordisk slashes Wegovy sales forecasts, blaming compounding - NPR
NPRarrow_outward
Novo Nordisk close
- 2025-08-18 21:10 event
- 40 sourceslanguage
- 200+ ads_click
- 2 weeks ago schedule